Please oe a plus sign (+) inside this box ->

Approval for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

10/016,985

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control

Application Numb r

Filing Date 12/07/01 TRANSMITTAL **FORM First Named Inventor** Walke Group Art Unit 1645 (to be used for all correspondence after initial filing) **Examiner Name** To be assigned Total Number of Pages in This Submission Attorney Docket Number LEX-0273-USA ENCLOSURES (check all that apply) After Allowance Communication **Assignment Papers** Fee Transmittal Form (for an Application) to Group Appeal Communication to Board Fee Attached Drawing(s) of Appeals and Interferences Appeal Communication to Group Amendment / Reply Licensing-related Papers (Appeal Notice, Brief, Reply Brief) After Final Petition Proprietary Information Petition to Convert to a Status Letter Affidavits/declaration(s) Provisional Application Power of Attorney, Revocation Other Enclosure(s) (please Extension of Time Request Change of Correspondence Address identify below): return postcard **Express Abandonment Request** Terminal Disclaimer PTO Form 1449 and 8 references International Search Report Supplemental Information Request for Refund Disclosure Statement Certified Copy of Priority CD, Number of CD(s) Document(s) Remarks Response to Missing Parts/ Incomplete Application Response to Missing Parts under 37 CFR 1.52 or 1.53 PATENT TRADEMARK OFFICE SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Firm Lance K. Ishimoto Reg. No. 41,866 Individual name Lexicon Genetics Incorporated Signature Date January 27, 2003

CERTIFICATE OF MAILING I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Box DD, P.O. Box 2327, Arlington, VA January 27, 2003 22202 on this date: Typed or printed name Nancy Stacey Date January 27, 2003 Signature

Burden Hour Statement: This form is estimated to the 0.2 hours to complete.) Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents. Washington, DC 20231.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Walke et al.

Application No.: 10/016,985

Filed: 12/07/01

Title: Novel Human Kinase and

Polynucleotides Encoding the Same

Attorney Docket No.: LEX-0273-USA

Commissioner for Patents Washington, D.C. 20231

Group Art Unit: 1645

Examiner: To Be Assigned:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Dear Sir:

This Supplemental Information Disclosure Statement is submitted:

<u>X</u>	under 37 CFR 1.97(b), or (Within three months of filing national application; or date of entry of international application; or before mailing date of first office action on the merits; whichever occurs last)
_	under 37 CFR 1.97(c) together with either a: Certification under 37 CFR 1.97(e), or a \$180.00 fee under 37 CFR 1.17(p), or (After the CFR 1.97(b) time period, but before final action or notice of allowance, whichever occurs first)
	under 37 CFR 1.97(d) together with a: Certification under 37 CFR 1.97(e), and a petition under 37 CFR 1.97(d)(2)(ii), and a \$130.00 petition fee set forth in 37 CFR 1.17(i)(1). (Filed after final action or notice of allowance, whichever occurs first, but before payment of the issue fee)

X Applicant(s) submit herewith Form PTO 1449-Supplemental Information Disclosure Citation together with copies, of patents, publications or other information of which applicant(s) are aware, which applicant(s) believe(s) may be material to the examination of this application and for which there may be a duty to disclose in accordance with 37 CFR 1.56.

The relevance of the attached references are that they were cited in a communication from a foreign patent office in a counterpart foreign application corresponding to the above-identified application.

Applicant submits that the above references taken alone or in combination neither anticipate nor render obvious the present invention. Consideration of the foregoing in relation to this application is respectfully requested.

It is requested that the information disclosed herein be made of record in this application.

Respectfully submitted,

January 27, 2003

Date

Lance K. Ishimoto

Reg. No. 41,866

LEXICON GENETICS INCORPORATED

(281) 863-3333

24231

PATENT TRADEMARK OFFICE

PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
demark Office; U.S. DEPARTMENT OF COMMERCE
fishlave a valid OMR control number

		us sign (+) inside this box work Reduction Act of 199		ons are required to res	Patent a	Approved for use a demark Office; U.S. displays a valid OME	S DEPARTM	1/99. OM	1B 0651-003 COMMERC	31
Substitute for form 1449A/PTO						Complete if Know		_	-	
JAN 3	0 2003				Application Numb r	10/016,985	雷	-	70	
4	l §	/ SUPPLEM			Filing Date	12/07/01	오		<u> </u>	_
(%).	INES	RMATION DEMENT BY	ISC	LOSURE	First Nam d Invent r	Walke	<u> </u>	5	$\dot{\sim}$	_
O TRA			455	LICANIT	Group Art Unit	1645		Z		
	SIAI	FIMENI BA	<u>AP</u>	LICANI	Examiner Name	To be assigned	긞	ಲಾ	111	
	Sheet	1	f	2	Attorney Docket Number	LEX-0273-USA	, 20	<u>اسا</u>	Z	
							<u> </u>	0		

				U.S. DATENT DOCUMEN	Te	<u> </u>			
	U.S. PATENT DOCUMENTS								
Examiner Initials*	Cite No.¹	U.S. Patent Number	Nind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of cited Document MM-DD-YYYY	Pager olumns, Lines, Vase Relevant Passages or Relevant Figures Appear			
-	СК	5,985,635		Bandman et al.	11/16/99				
	 				 				
	<u> </u>	 			+				
		<u> </u>							
					T				
		 							
	<u> </u>								
					 				

				FORE	IGN PATENT DOCUMENTS	3	- · · ·	
Examiner	Cite	Foreign Patent Document			Name of Patentee or	Date of Publication of	Pages, Columns, Lines, Where Relevant	
Initials*	No.1	Office	ce ³ Number ⁴ Kind Coi (if know		Applicant of Cited Document	cited Document MM-DD-YYYY	Passages or Relevant Figures Appear	T⁵
	CL	wo	01/38503	A2	Sugen Inc.	05/31/01		
	СМ	wo	01/88148	A2	Applera Corporation	11/22/01		
	CN	wo	02/10401	A2	Millennium Pharmaceuticals	02/07/02		
	co	JP	2000 060571		Mitsubishi Chemicals	02/29/00	Abstract	

Examiner		Date	
Signature		Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/99. OMB 0651-0031

~	Indier Vec	anenwork Reduction Act of 1	1995, no	persons are required to	respond to a collection of information	Pales and Trademark Office; Usunless it displays a valid OMB of	S. DEPARTME control number.	ENT OF CO	DMME
•		for form 1449B/PTO			,	Complete if Known	E0		ñ
JAN	3 0 2003	SUPPLEM	IEN'	ΤΔΙ	Application Number	10/016,985	0	7	$\overline{\mathbf{O}}$
	2000	MATION D			Filing Date	1 <u>2</u> /07/01	四四	Z	m
	INFC	WIATION D	150	LOSURE	First Named Inventor	Walke	#	60	=
· A	STA	EMENT BY	API	PLICANT	Group Art Unit	1645	70		Z
				,	Examiner Name	To be assigned	<u></u>	<u> </u>	口
i	Sheet	2	of	2	Attorney Docket Number	1 EX-0273-USA	6		T

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	СР	Database EMBL 'Online' EM_RO, 01/08/99, retrieved from EBI Database accession no. AB010154, XP002222847, abstract	
_	CQ	Database EMBL 'Online', Swall, 05/01/99, retrieved from EBI Database accession no. Q9Z335, XP002222848, abstract	T
	CR	Scott et al., "Serine/threonine protein kinases," Current Opinion in Neurobiology, England, June 1992, Vol. 2, No. 3, pgs. 289-295, XP001131989, ISSN: 0959-4388	
		International Search Report, International Application No. PCT/US01/48533, 12/07/01 (Attorney Docket No. LEX-0273-PCT)	
			-
			<u> </u>
			-
			-
į			
			\vdash

Examiner	Date
Signature	Considered

^{*}EXAMINER: Initial reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20221. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.